FDA clears updated FFR guidewire

Justine Varieur Cadet | | Health Imaging | Diagnostic Imaging
St. Jude Medical has received FDA clearance for multiple enhancements to its PressureWire fractional flow reserve (FFR) measurement guidewire.

FFR measurement identifies the severity of narrowings in the coronary arteries to allow for the assessment of coronary lesions for the treatment of coronary artery blockages, according to St. Jude, which is based in St. Paul, Minn.

The PressureWire with Agile Tip was designed to replicate the performance of standard PCI guidewires, the company said. The device is available in both of the company’s Aeris (wireless) and Certus PressureWire models. Another new feature in the next-generation PressureWire is a hydrophilic coating.

Justine Varieur Cadet

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.